SS-31

The longest trial of SS-31 ran continuously for 168 weeks (over 3 years) with no reported tolerance issues. This is cited as evidence that cycling may not be strictly necessary.

A human trial compared 4 mg/day vs 40 mg/day of SS-31 and found that the higher dose showed no observable advantages over the lower dose. This supports using lower therapeutic doses for non-clinical populations.

The speaker outlines a comprehensive five-tier stacking protocol designed for cellular energy optimization. Tier one is foundational supplements; tier two adds NAD+ (50–100 mg SC, 3–5x/week); tier three adds Epitalon (500 mcg–1 mg/day, 10–20 days) and FOXO4-DRI (2–5 mg EOD, 3 doses); tier four adds SS-31 (2 mg/day SC) and MOTS-c (10 mg/week, MWF); tier five conditionally adds Five Amino 1MQ (50–100 mg/day), methylene blue (5–10 mg/day), and injectable L-carnitine (200–500 mg, 3–5x/week). All peptide tiers are cycled eight to twelve weeks on and four to eight weeks off.

The speaker issues a general safety and efficacy caveat that training, nutrition, and sleep must be established before any peptide or supplement protocol is layered on top. The explicit claim is that these protocols enhance existing work but cannot replace it. This functions as a contraindication-adjacent warning against using peptides as a substitute for foundational health behaviors.

The speaker explicitly frames the entire five-tier protocol as modular, meaning individuals do not need to implement all tiers simultaneously to observe results. Each tier is designed to build upon the previous, but partial adoption is presented as valid. This is a structural recommendation rather than a mechanistic or clinical claim.

The speaker explicitly recommends running SS-31 and MOTS-c concurrently as a combined tier-four energy stack. SS-31 is dosed at 2 mg per day subcutaneous while MOTS-c is dosed at 10 mg per week split three days. Both are cycled identically at eight to twelve weeks on and four to eight weeks off.

SS-31 (also known as Elamipretide) is presented as a core tier-four energy stack peptide targeting mitochondrial function. The recommended dose is approximately 2 mg per day administered subcutaneously. It is cycled on the same schedule as NAD+: eight to twelve weeks on, four to eight weeks off.

The speaker repeatedly uses the qualifier 'hypothetically' when stating peptide dosages (SS-31 at 2 mg/day, MOTS-c at 1 mg/day, Cax at 400 mcg/day), framing the recommendations as hypothetical for a 'kangaroo' rather than direct human prescriptions. This appears to be a legal disclaimer strategy. The dosages are nonetheless presented with specificity and clinical intent within the context of a burnout recovery protocol.

NAD+ is described as a critical co-intervention alongside the peptide stack (SS-31 and MOTS-c), serving as the electron acceptor in the glycolytic pathway and electron transport chain. Without NAD+, the speaker states energy production from glucose is impossible. Additionally, NAD+ is identified as a substrate for PARP (poly ADP-ribose polymerase) and sirtuins — repair enzymes that fix oxidative DNA damage caused by burnout. Dosage is 50 mg/day taken together with MOTS-c and SS-31.

The speaker issues a direct warning against stacking too many compounds simultaneously, including peptides, citing the example of patients taking 14+ supplements including 'a whole bunch of peptides.' He argues this creates metabolic chaos, overloads the liver and kidneys, and adds additional processing burden to already-failing mitochondria. The warning is framed as a safety and efficacy concern: more compounds do not equal more optimization and can actively worsen the underlying mitochondrial failure being treated.

The speaker presents a comprehensive multi-compound protocol targeting each biochemical mechanism of burnout: SS-31 (2 mg/day) and MOTS-c (1 mg/day) for mitochondrial repair; NAD+ (50 mg/day) for electron transport and DNA repair enzyme activation; CoQ10 (200 mg/day) and PQQ (20 mg/day) for electron carrier substrate and biogenesis signaling; L-Tyrosine (3 g/day) as dopamine/norepinephrine precursor; Cax (400 mcg/day morning) for BDNF-mediated dopaminergic recovery; Magnesium Bisglycinate (500 mg before bed) as NMDA antagonist; and L-Theanine (200 mg before bed) for GABA promotion and glutamate excitotoxicity reduction. The speaker states this protocol takes 20–30 days.

The speaker explicitly recommends stacking SS-31 and MOTS-c together as a combined intervention targeting mitochondrial repair. SS-31 addresses the structural membrane damage while MOTS-c drives biogenesis of new mitochondria. The combined framing is summarized as 'SS31 and MOTS-c repair the furnace.' Dosages are 2 mg/day SS-31 and 1 mg/day MOTS-c, both taken daily.

SS-31 is described as binding to cardiolipin, the phospholipid layer of the mitochondrial inner membrane that becomes damaged by oxidative stress during burnout. The speaker claims it stabilizes membrane structure, prevents further reactive oxygen species leakage, and reduces new ROS production. A hypothetical dosage of 2 mg every single day is mentioned. The speaker frames this as a targeted intervention for the exact biochemical mechanism of mitochondrial failure.

The speaker issues a clear advisory that training, nutrition, and sleep are non-negotiable prerequisites before any peptide or supplement protocol is initiated. Peptides are framed as enhancers of existing healthy behaviors, not replacements for them. This is presented as a foundational safety and efficacy principle throughout the protocol.

The speaker explicitly frames the entire protocol as modular, meaning users do not need to implement all tiers simultaneously to see results. Each tier builds on the previous but can be used in isolation. This is presented as a practical safety and accessibility consideration rather than a clinical recommendation.

The speaker explicitly recommends stacking SS-31 and MOTS-c together as the core tier-four energy intervention, running them concurrently rather than sequentially. SS-31 is dosed at ~2 mg/day subcutaneous and MOTS-c at ~10 mg/week (split MWF). Both follow the same eight to twelve weeks on, four to eight weeks off cycling schedule.

SS-31 (Elamipretide) is presented as a core tier-four energy stack peptide targeting mitochondrial function. The recommended dose is approximately 2 mg per day via subcutaneous injection. It is cycled on an eight to twelve weeks on, four to eight weeks off schedule, mirroring the NAD+ cycling protocol.

SS-31 (Elamipretide) is characterized as the 'engine repair' component of the Mechanic Protocol, targeting structural damage in mitochondria. The speaker frames it as complementary to MOTS-c's functional efficiency improvements. No dosage or specific study was cited for SS-31 in this video.

The speaker's original 'Mechanic Protocol' recommended taking SS-31 first to repair mitochondrial structural damage, then adding MOTS-c afterward to optimize. Based on the new animal study showing MOTS-c has direct functional benefits (not just signaling), the speaker now recommends running both peptides simultaneously from day one. The rationale is that SS-31 repairs structural damage while MOTS-c improves functional efficiency — hitting the same problem from two complementary angles. No dosages were mentioned.

The standard Barth syndrome dose of ~40 mg/day is not applicable to therapeutic users. Barth syndrome patients lack endogenous mitochondrial repair capacity, requiring much higher doses. Healthy individuals using SS-31 therapeutically need far less (1-5 mg/day).

The speaker states that existing data does not indicate a need to cycle off either SS-31 or MOTS-C. The 8-12 weeks on / 4-8 weeks off cycling recommendation is a precautionary measure due to the absence of long-term human dosing data at these specific doses.

SS-31 binds to cardiolipin, a lipid molecule in mitochondrial membranes, rather than to a receptor. This means there is no receptor desensitization or downregulation, which theoretically supports continuous use without tolerance development.

For therapeutic (non-Barth syndrome) use, SS-31 is recommended at 1-2 mg/day for 4-8 weeks. More aggressive dosing can go up to 5 mg/day. The standard Barth syndrome dose of 40 mg/day is unnecessary for healthy individuals because they retain endogenous mitochondrial repair capacity.

The speaker recommends stacking SS-31 (daily) with MOTS-C (3x/week) for synergistic mitochondrial benefits. SS-31 at 1-2 mg/day and MOTS-C at 5-15 mg/week split across three doses. For significant age-related decline, doses can be pushed to SS-31 at 5 mg/day and MOTS-C at 15 mg/week. Recommended cycle: 8-12 weeks on, 4-8 weeks off.

The complete EBV protocol combines four peptides with nutritional support: Thymosin Alpha-1 (1 mg 2x/week, 12 weeks) for T-cell retraining, KPV (400 mcg 2x/day) for inflammatory cytokine suppression, SS-31 + MOTS-c (stacked) for mitochondrial repair. Supplements include monolaurin (titrate 500 mg to 2-3 g/day), L-lysine (2-3 g/day in 3 doses), selenium (200 mcg/day), and DGL (600 mg/day). A 2022 study (Prusty, Viruses) showed combination antiviral + immune-supportive therapy achieved 67% viral load reduction and 71% symptom improvement sustained at 12-month follow-up.

Dr. Bachmeyer explicitly states that SS-31 and MOTS-c need to be used together ('married') for EBV-related mitochondrial dysfunction. SS-31 addresses the structural membrane damage while MOTS-c addresses biogenesis and metabolic software. Without both, recovery from viral-induced mitochondrial damage is incomplete.

Chronic EBV infection punches holes in mitochondrial membranes via oxidative stress, causing energy collapse (ATP production reduced 34%, ROS increased 156% per a 2020 Navo study). SS-31 protects the inner mitochondrial membrane from this viral-induced oxidative damage. Dr. Bachmeyer states SS-31 must be paired with MOTS-c for full mitochondrial restoration. No specific dose given for SS-31.

The speaker discloses that he owns Elite Biogenics, the company from which he sources the compounds discussed in the protocol including peptides. He states the company has its own labs and warehouses and that he personally trusts the products enough to give to his family. This is a relevant conflict-of-interest disclosure for evaluating the objectivity of the peptide recommendations made throughout the video.